Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026
Company Drug

HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC

Fineline Cube Mar 31, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...

Company Deals

Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’

Fineline Cube Mar 31, 2023

Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...

Company Drug

Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Mar 31, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Company Deals

Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership

Fineline Cube Mar 31, 2023

Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...

Company Drug

Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...

Company Deals

Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration

Fineline Cube Mar 31, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment

Fineline Cube Mar 31, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...

Medical Device

IceCure Medical Gains NMPA Approval for Cryoablation Technology in China

Fineline Cube Mar 31, 2023

Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...

Company Deals

SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal

Fineline Cube Mar 31, 2023

China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research...

Company Deals

Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade

Fineline Cube Mar 30, 2023

QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi...

Company Drug

ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development

Fineline Cube Mar 30, 2023

China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...

Policy / Regulatory

Round 8 VBP Tender Results Announced with RMB 21.6 Billion Market

Fineline Cube Mar 30, 2023

The National Allied Procurement Office has issued an initial notification upon the completion of Round...

Company

Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials

Fineline Cube Mar 30, 2023

Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,...

Company Drug

Janssen to Halt RSV Adult Vaccine Development, Impacting Phase III Trial

Fineline Cube Mar 30, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its...

Company

Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results

Fineline Cube Mar 30, 2023

China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total...

Company Drug

Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment

Fineline Cube Mar 30, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib,...

Company Deals

Boston Scientific Partners with Scivita Medtech for Disposable Electronic Cholangioscope

Fineline Cube Mar 30, 2023

Boston Scientific Corporation (NYSE: BSX), a leading figure in the medical device industry, has announced...

Company Drug

Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Mar 30, 2023

China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...

Company Deals

CNBG Partners with China CDC to Strengthen Disease Prevention and Public Health

Fineline Cube Mar 30, 2023

China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the...

Posts pagination

1 … 540 541 542 … 663

Recent updates

  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
  • Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Medical Device

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.